| Code | CSB-RA013227MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to the reference antibody described in US7429644B2, designed to specifically target lymphotoxin beta receptor (LTBR). LTBR is a member of the tumor necrosis factor receptor superfamily that plays critical roles in lymphoid organogenesis, immune system development, and inflammatory responses. Upon binding with its ligands, lymphotoxin-alpha1-beta2 heterotrimers or LIGHT, LTBR activates both canonical and non-canonical NF-κB signaling pathways. This receptor is implicated in various pathological conditions including autoimmune diseases, chronic inflammation, viral infections, and certain cancers where it influences tumor microenvironment dynamics and immune cell interactions.
The reference antibody in US7429644B2 has been characterized for its ability to modulate LTBR signaling pathways, making this biosimilar a valuable tool for investigating LTBR-mediated cellular processes. Researchers can utilize this antibody to explore lymphoid tissue architecture, study immune cell development and organization, and examine the therapeutic potential of LTBR pathway modulation in inflammatory and oncological disease models.
There are currently no reviews for this product.